NCT04749173View on ClinicalTrials.gov

To Assess the Safety, Tolerability and Pharmacokinetic Properties of Niclosamide Injectable (DWRX2003) Which is the Treatment of COVID-19 in Healthy Volunteers.

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 21, 2020

Primary Completion Date

June 18, 2021

Study Completion Date

June 18, 2021

Conditions
Covid19
Interventions
DRUG

DWRX2003, 96mg

Drug: Placebo Intramuscularly injection at predefined injection sites

DRUG

DWRX2003, 432mg

Drug: Placebo Intramuscularly injection at predefined injection sites

DRUG

DWRX2003, 144mg

Drug: Placebo Intramuscularly injection at predefined injection sites

DRUG

DWRX2003, 144mg

Drug: Placebo Intramuscularly injection at predefined injection sites

Trial Locations (1)

Unknown

Chungnam National university hospital, Daejeon

Sponsors
All Listed Sponsors
lead

Daewoong Pharmaceutical Co. LTD.

INDUSTRY

NCT04749173 - To Assess the Safety, Tolerability and Pharmacokinetic Properties of Niclosamide Injectable (DWRX2003) Which is the Treatment of COVID-19 in Healthy Volunteers. | Biotech Hunter | Biotech Hunter